Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10931)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22241)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5650)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (641)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study
    Meeting Abstract

    Rojas, C.; Eskens, F.; Ghiringhelli, F.; Özgüroglu, M.; Caglevic, C.; Gumus, M.; Tosi, D.; Grenier, J.; Gonzalez, A. F.; Arenas, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)
    Meeting Abstract

    Erickson, B. K.; Enserro, D.; Lankes, H. A.; Dockery, L. E.; Ghamande, S. A.; Oliver, M. T.; Gressel, G. M.; Castellano, T.; Ratner, E.; Deery, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Meeting Abstract

    Motzer, R. J.; Penkov, K.; Uemura, H.; Campbell, M. T.; Kollmannsberger, C. K.; Lee, J. L.; Venugopal, B.; Van Den Eertwegh, A.; Negrier, S.; Gurney, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)
    Meeting Abstract

    Colevas, A. D.; Chung, C. H.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Sukari, A.; Worden, F. P.; Johnson, F. M.; Saba, N. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Tap, W. D.; Somaiah, N.; Kang, Y. K.; Ryan, A.; Razak, A.; Garrido, M.; Desar, I. M. E.; Italiano, A.; Reichardt, P.; Wilky, B. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)
    Meeting Abstract

    Lacuna, K. P.; Ingham, M.; Chen, L.; Das, B.; Lee, S. M.; Ge, L.; Druta, M.; Conley, A. P.; Keohan, M. L.; Agulnik, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis
    Meeting Abstract

    Makker, V.; Richardson, D. L.; Chon, H. S.; Miller, D. S.; Mau-Sorensen, M.; Cibula, D.; Zagouri, F.; Fidalgo, A. P.; Slomovitz, B. M.; Coleman, R. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)
    Meeting Abstract

    Lee, J. Y.; Ryoo, B. Y.; Kim, J. W.; Cheng, A. L.; Finn, R. S.; Hasegawa, K.; Makker, V.; Kudo, M.; Miller, D. S.; Merle, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 safety and efficacy of IMC-F106C, a PRAME x CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
    Meeting Abstract

    Hamid, O.; Williams, A.; Lopez, J. S.; Olson, D.; Sato, T.; Shaw, H. M.; Friedman, C. F.; Thistlethwaite, F.; Middleton, M. R.; Lebbe, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies
    Meeting Abstract

    Drilon, A. E.; Dziadziuszko, R.; Camidge, D. R.; Lin, J. J.; Besse, B.; Kim, S. W.; Lee, K. H.; Solomon, B. J.; Nagasaka, M.; Goto, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save